Zoetis Inc. $ZTS Shares Acquired by Dividend Assets Capital LLC

Dividend Assets Capital LLC grew its position in shares of Zoetis Inc. (NYSE:ZTS) by 21.1% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,991 shares of the company’s stock after purchasing an additional 9,052 shares during the period. Dividend Assets Capital LLC’s holdings in Zoetis were worth $6,146,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Brighton Jones LLC increased its stake in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after purchasing an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its position in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after buying an additional 657 shares during the last quarter. Intech Investment Management LLC boosted its holdings in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after buying an additional 1,224 shares during the period. Sivia Capital Partners LLC boosted its holdings in shares of Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after buying an additional 1,422 shares during the period. Finally, Glenview Trust co grew its position in shares of Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock valued at $745,000 after buying an additional 506 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Zoetis

Here are the key news stories impacting Zoetis this week:

• Neutral Sentiment: Barclays reiterated its Hold rating on Zoetis, signaling the firm still sees limited near-term upside after the company’s recent earnings miss and softer-than-expected revenue growth. Barclays Sticks to Its Hold Rating for Zoetis (ZTS)
• Neutral Sentiment: Zoetis also drew attention for its dividend profile, with commentary focused on dividend quality as a potential support for income-oriented investors. Zoetis Inc (NYSE:ZTS) Dividend Quality Draws Focus
• Negative Sentiment: Multiple law firms issued reminders about an investor lawsuit deadline tied to alleged securities fraud, with claims centered on possible misstatements and omissions about product adoption. These notices can add overhang and keep sentiment weak around ZTS. ZTS IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Zoetis Inc. Investors…
• Negative Sentiment: Additional class-action announcements from other firms reinforced the same legal overhang, keeping attention on the July 27 lead-plaintiff deadline rather than on business fundamentals. Zoetis Inc. (ZTS) Investors: July 27, 2026, Filing Deadline in Securities Fraud Class Action…

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on ZTS shares. Morgan Stanley reaffirmed an “overweight” rating and issued a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Citigroup decreased their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a research report on Monday, May 18th. UBS Group dropped their price target on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating on the stock in a research note on Friday, May 8th. Finally, Weiss Ratings downgraded Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, June 12th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis has a consensus rating of “Hold” and an average target price of $126.92.

Zoetis Price Performance

NYSE:ZTS opened at $74.73 on Monday. The company has a quick ratio of 1.91, a current ratio of 3.15 and a debt-to-equity ratio of 2.80. The business’s 50-day moving average price is $84.04 and its 200 day moving average price is $109.31. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $161.77. The firm has a market cap of $31.33 billion, a P/E ratio of 12.39, a PEG ratio of 1.17 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue was up 2.9% compared to the same quarter last year. During the same period in the previous year, the company posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, sell-side analysts predict that Zoetis Inc. will post 6.88 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be paid a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.8%. Zoetis’s dividend payout ratio is currently 35.16%.

Insider Buying and Selling

In other Zoetis news, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the transaction, the director owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Frank A. Damelio purchased 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 11,650 shares of company stock worth $886,384. Corporate insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.